Literature DB >> 10777214

Epstein-Barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein associated with Hepatitis B virus X antigen.

E Kashuba1, V Kashuba, K Pokrovskaja, G Klein, L Szekely.   

Abstract

EBNA-3 (also called EBNA-3A) is one of the EBV encoded nuclear antigens that are necessary for B-cell transformation. EBNA-3 is known to target RBPs, nuclear proteins that also interacts with EBNA-2, EBNA-4 and EBNA-6. In order to identify additional EBNA-3 targets, an EBV-transformed human lymphocyte cDNA library was screened in the yeast two-hybrid system with N-terminus truncated EBNA-3 that cannot interact with RBP-Jkappa. A clone, encoding Xap-2 protein, a cellular partner of Hepatitis B virus X-antigen was isolated. This protein is also known as the p38 subunit of the aryl hydrocarbon receptor complex (ARA9). The specific binding to EBNA-3 was confirmed by showing that the GST-Xap-2 precipitated EBNA-3 from CV1 cells that were infected with recombinant vaccinia virus expressing EBNA-3. Deletion of the C-terminus of Xap-2 eliminated the binding. Fusion with green fluorescent protein showed that Xap-2 is preferentially cytoplasmic but translocates to the nucleus upon expression of EBNA-3.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777214     DOI: 10.1038/sj.onc.1203501

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes.

Authors:  Surya Pavan Yenamandra; Ulf Hellman; Bettina Kempkes; Suhas Deoram Darekar; Sabine Petermann; Tom Sculley; George Klein; Elena Kashuba
Journal:  Cell Mol Life Sci       Date:  2010-07-01       Impact factor: 9.261

Review 2.  Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration.

Authors:  Melanie Gerard; Angélique Deleersnijder; Jonas Demeulemeester; Zeger Debyser; Veerle Baekelandt
Journal:  Mol Neurobiol       Date:  2011-05-07       Impact factor: 5.590

3.  Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical.

Authors:  Seiji Maruo; Eric Johannsen; Diego Illanes; Andrew Cooper; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth.

Authors:  Seiji Maruo; Eric Johannsen; Diego Illanes; Andrew Cooper; Elliott Kieff
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Aryl Hydrocarbon Receptor Interacting Protein Targets IRF7 to Suppress Antiviral Signaling and the Induction of Type I Interferon.

Authors:  Qinjie Zhou; Alfonso Lavorgna; Melissa Bowman; John Hiscott; Edward W Harhaj
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

Review 6.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

Review 7.  New insights into the aryl hydrocarbon receptor as a modulator of host responses to infection.

Authors:  B Paige Lawrence; Beth A Vorderstrasse
Journal:  Semin Immunopathol       Date:  2013-08-21       Impact factor: 9.623

Review 8.  The aryl hydrocarbon receptor is a modulator of anti-viral immunity.

Authors:  Jennifer L Head; B Paige Lawrence
Journal:  Biochem Pharmacol       Date:  2008-11-05       Impact factor: 5.858

Review 9.  The Aryl Hydrocarbon Receptor as a Modulator of Anti-viral Immunity.

Authors:  Maria Florencia Torti; Federico Giovannoni; Francisco Javier Quintana; Cybele Carina García
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

10.  Epstein-Barr virus immortalization of human B-cells leads to stabilization of hypoxia-induced factor 1 alpha, congruent with the Warburg effect.

Authors:  Suhas Darekar; Konstantinos Georgiou; Mariya Yurchenko; Surya Pavan Yenamandra; Georgia Chachami; George Simos; George Klein; Elena Kashuba
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.